Figure 1.
Criteria for continuing or ceasing additional investigation of bumped-kinase inhibitor (BKIs). A, The colors reflect distinct stages of evaluating BKIs for their suitability as a therapy for cryptosporidiosis. Criteria for advancement (ie, continuing additional investigation) are listed for each assay. B, Summary of the progression of each individual BKI. Colored blocks are filled in when the BKI satisfies the criteria for advancement and left blank when the BKI fails to meet the criteria and was eliminated from additional investigation. Abbreviations: CC50, 50% cytotoxicity concentration; Cmax, maximum concentration; CpCDPK1, Cryptosporidium parvum calcium-dependent protein kinase 1; C. parvum, Cryptosporidium parvum; EC50, 50% effective concentration; IC50, 50% inhibitory concentration; IFN-γ, interferon γ; KO, knockout. aIncluded as a control.